Column: This is how the Danish Medicines Council should strengthen its application process
Roche and Novartis have been behind almost 10 percent of all application submissions to the Danish Medicines Council since 2017. In a column, representatives from both firms point out three problems and make concrete proposals for how to improve the council’s work.
by Darine Ghanem, General Manager for Roche Pharma Denmark & Iceland, and Peter Drøidal, Country Manager for Denmark & Nordic Head Market Access at Novartis, translated by daniel pedersen
In 2021, the Danish Medicines Council processed 50 new drug applications. Unfortunately, the established allotted case processing time of 84 days was exceeded with every application. This is the fifth year in a row that case processing got behind schedule, according to the council’s latest year-in-review.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Novartis increases sales of Genmab-developed sclerosis drug
For subscribers
